19.32USD+3.65%Mkt Cap: 3.09B USDP/E: —Last update: 2026-05-26
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor p…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap3.09B USD
Enterprise Value2.12B USD
Revenue (TTM)—
Gross Profit-406.40M USD
Net Income (TTM)-512.54M USD
Revenue/Share—
Last Price19.32 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees507
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS24823R1059
Valuation
P/E (Trailing)—
P/E (Forward)-7.79
PEG—
EV/EBITDA-3.98
EV/Revenue—
P/S—
P/B2.97
EPS (TTM)-2.88
EPS (Forward)-2.48
52W Range
12.5860% of range23.77
52W High23.77 USD
52W Low12.58 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-50.56%
ROA-44.77%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-412.60M USD
CapEx (TTM)9.50M USD
FCF Margin—
FCF Yield-6.16%
Net Debt-947.64M USD
Net Debt/EBITDA1.78
Balance Sheet
Debt/Equity0.04
Current Ratio9.29
Quick Ratio8.98
Book Value/Sh6.491 USD
Cash/Share6.223 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)35.43 USD
Target Range23.00 USD – 42.00 USD
# Analysts14
Ownership
Shares Out.158.71M
Float144.27M
Insiders9.13%
Institutions99.54%
Short Interest
Short Ratio9.9d
Short % Float9.85%
Short % Out.9.34%
Shares Short14.81M
Short (prev mo.)15.42M
Technical
SMA 5019.74 (-2.1%)
SMA 20017.81 (+8.5%)
Beta0.99
S&P 52W Chg28.31%
Avg Vol (30d)1.72M
Avg Vol (10d)1.73M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—